Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

Table 3

Specific adverse events during ruxolitinib treatment.

	All patients		IPSS category
			Low risk		Intermediate-1 risk
		%		%		%
Total patients	108	100.00	25	100.00	83	100.00
Grade 3 or higher thrombocytopenia	8	7.41	3	12.00	5	6.02
Grade 3 or higher anemia	24	22.22	5	20.00	19	22.89
Ruxolitinib treatment changes due to adverse reactions
Dose reduction	19	17.59	3	12.00	16	19.28
Temporary therapy interruption	1	0.93	1	4.00	0	0.00
Therapy discontinuation	1	0.93	1	4.00	0	0.00

IPSS, International Prognostic Scoring System.
Defined as a platelet count < 50 × 10⁹/L at any point after ruxolitinib initiation through last ruxolitinib dose.
Defined as hemoglobin < 8 g/dL at any point after ruxolitinib initiation through last ruxolitinib dose.